Published in Pain and Central Nervous System Week, October 23rd, 2006
"Neuroblastoma is a heterogeneous disease in which 22% of tumors show MycN oncogene amplification and are associated with poor clinical outcome. MycN is a transcription factor that regulates the expression of a number of proteins that affect the clinical behavior of neuroblastoma," researchers in the United States explained.
"We report here that CRABP-II is a novel MycN target, expressed at significantly higher levels in primary neuroblastoma tumors with mycN oncogene amplification as compared with non-MycN-amplified tumors....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain and Central Nervous System Week